Pimecrolimus in an adhesive ointment as a new treatment option for oral lichen planus [9]

British Journal of Dermatology

Volumn 150, Issue 4, 2004, Pages 782-784

  Dissemond, J ^a   Schroter S ^a   Franckson, T ^a   Herbig, S ^a   Goos, M ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PIMECROLIMUS;

AGED; BURNING SENSATION; CASE REPORT; CLINICAL FEATURE; DISEASE COURSE; FEMALE; HUMAN; HYDROGEL; LABORATORY TEST; LETTER; LICHEN PLANUS; MOUTH MUCOSA; PRIORITY JOURNAL; TREATMENT FAILURE; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; DERMATOLOGIC AGENTS; FEMALE; HUMANS; LICHEN PLANUS, ORAL; OINTMENTS; TACROLIMUS; TREATMENT OUTCOME;

EID: 2342572348     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0007-0963.2004.05884.x     Document Type: Letter

References (10)

1. Vente C, Reich K, Rupprecht R, Neumann C. Erosive mucosal lichen planus: response to topical treatment with tacrolimus. Br J Dermatol 1999; 140: 338-42.
2. Hegarty AM, Hodgson TA, Lewsey JD, Porter SR. Fluticasone propionate spray and betamethasone sodium phosphate mouth-rinse: a randomized crossover study for the treatment of symptomatic oral lichen planus. J Am Acad Dermatol 2002; 47: 271-9.
3. Chan ESY, Thornill M, Zakrzewska J. Interventions for treating oral lichen planus. The Cochrane Library 2003: 1.
4. Cribier B, Frances C, Chosidow O. Treatment of lichen planus. An evidence-based medicine analysis of efficacy. Arch Dermatol 1998; 134: 1521-30.
5. Olivier V, Lacour JP, Mousnier A et al. Treatment of chronic erosive oral lichen planus with low concentrations of topical tacrolimus: an open prospective study. Arch Dermatol 2002; 138: 1335-8.
6. Bornhövd EC, Burgdorf WH, Wollenberg A. Macrolactam immunomodulators for topical treatment of inflammatory skin diseases. J Am Acad Dermatol 2001; 45: 736-43.
7. Kay JE. Structure-function relationships in the FK506-binding protein (FKBP) family of peptidylprolyl cis-trans isomerases. Biochem J 1996; 314: 361-85.
8. Queille-Roussel C, Paul C, Duteil L et al. The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double-blind controlled study. Br J Dermatol 2001; 144: 507-13.
9. Rappersberger K, Komar M, Ebelin ME et al. Pimecrolimus identifies a common genomic anti-inflammatory profile, is clinically highly effective in psoriasis and is well tolerated. J Invest Dermatol 2002; 119: 876-87.
10. Stuetz A, Grassberger M, Meingassner JG. Pimecrolimus (Elidel. SDZ ASM 981) - preclinical pharmacologic profile and skin selectivity. Semin Cutan Med Surg 2001; 20: 233-41.